Deal watch: Abbott and Neurocrine to develop promising endometriosis drug

Nature reviews. Drug discovery · 2010 · vol. 9(8) , pp. 585 · doi:10.1038/nrd3246 · PMID:20671753 · W4252496280
Other OA: bronze CC0
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-28 ⓘ

Abbott and Neurocrine announced a partnership to develop a promising drug candidate for the treatment of endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gonadotropin-Releasing Hormone Hydrocarbons, Fluorinated Pyrimidines Clinical Trials as Topic Clinical Trials as Topic Cooperative Behavior Cooperative Behavior Drug Design Drug Design Drug Industry Drug Industry Drug Industry Endometriosis Endometriosis Endometriosis Female Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-11-12T06:12:04.065205+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:07:47.794683+00:00
License: CC0 · commercial use OK